Apogee Therapeutics shares are trading higher after the company released 16-week data from Part A of the Phase 2 APEX clinical trial of APG777 for moderate-to-severe atopic dermatitis.

ارتفعت أسهم شركة Apogee Therapeutics بعد أن أصدرت الشركة بيانات مدتها 16 أسبوعًا من الجزء A من المرحلة الثانية من التجربة السريرية APEX لـ APG777 لعلاج التهاب الجلد التأتبي من المتوسط إلى الشديد.

+2.13% Post

Apogee Therapeutics

APGE

38.43

+2.13%

0.00% Post

Apogee Therapeutics shares are trading higher after the company released 16-week data from Part A of the Phase 2 APEX clinical trial of APG777 for moderate-to-severe atopic dermatitis.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.